http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104998255-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6087 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-116 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate | 2015-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104998255-B |
| titleOfInvention | New A CYW135 group meningitis cocci combined vaccines and preparation method thereof |
| abstract | The invention discloses a kind of ACYW135 group meningitis coccis combined vaccines, the vaccine is 4 valence combined vaccines, the polysaccharide protein conjugate that the capsular polysaccharide containing A, C, Y and W135 group meningitis cocci is obtained with a kind of outer membrane vesicle albumen coupling in membrane vesicle albumen outside B groups of 4 types of serotype and 15 types respectively.Meningococcus combined vaccine provided by the present invention has effectively evaded the risk of the influence vaccine immune response caused by immune tolerance and antigen site existing for single carrier protein prepares multivalence combined vaccine compete; and using TT, DT as carrier protein prepare combined vaccine existing for allergic reaction and Poison Reverse etc. security risks; and A groups of immunizations can be promoted, provide wide range is directed to the B groups of bactericidins for having protective effect.Complete ACYW135 group meningitis coccis combined vaccine production technology is provided simultaneously, and adapts to large-scale production.Studies have shown that this vaccine has good immunogenicity and the immune persistence of reliable safety and stabilization. |
| priorityDate | 2015-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.